Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2024 | Xaluritamig (AMG 509) and its role in targeting prostate cancer

Andrew Armstrong • 15 Sep 2024
ESMO 2024
Genitourinary Cancer Prostate Cancer Antibodies Xaluritamig

Andrew Armstrong, MD, Duke Cancer Institute, Durham, NC, gives an overview of xaluritamig (AMG 509), a bispecific T-cell engager targeting STEAP1, an androgen receptor (AR)-regulated cell surface protein highly expressed in advanced prostate cancer. Xaluritamig enhances immune response by directing T-cells to the tumor microenvironment, facilitating the destruction of prostate cancer cells. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Andrew Armstrong

Key prostate cancer trials at ASCO 2026: PROTEUS, TALAPRO-3, and A-DREAM
5:41
Key prostate cancer trials at ASCO 2026: PROTEUS, TALAPRO-3, and A-DREAM
Andrew Armstrong • 3 Jun 2026
Smoking-associated genomic alterations linked to poorer outcomes in metastatic prostate cancer
2:19
Smoking-associated genomic alterations linked to poorer outcomes in metastatic prostate cancer
Andrew Armstrong • 3 Jun 2026
Enzalutamide outcomes & duration predictors in mHSPC: ARCHES post hoc analyses
3:04
Enzalutamide outcomes & duration predictors in mHSPC: ARCHES post hoc analyses
Andrew Armstrong • 3 Jun 2026
Chemo-IO in neuroendocrine or aggressive variant metastatic prostate cancer
2:24
Chemo-IO in neuroendocrine or aggressive variant metastatic prostate cancer
Andrew Armstrong • 3 Jun 2026

Related Videos

Current and emerging systemic strategies in biochemically relapsed prostate cancer
2:45
Current and emerging systemic strategies in biochemically relapsed prostate cancer
Ashwin Sachdeva • 16 May 2026
How has SABR improved radiotherapy practice in kidney cancer?
1:06
How has SABR improved radiotherapy practice in kidney cancer?
Shankar Siva • 16 May 2026
Which patients with kidney cancer may benefit from SABR treatment?
1:58
Which patients with kidney cancer may benefit from SABR treatment?
Shankar Siva • 16 May 2026
Management of brain metastasis in patients with poor-risk testicular cancer
1:03
Management of brain metastasis in patients with poor-risk testicular cancer
Darren Feldman • 30 May 2026
The content of VJOncology is intended for healthcare professionals